FDA Wants Your Thoughts on Medical Device Paperwork—Again
Published Date: 2/26/2026
Notice
Summary
The FDA is asking for public feedback on their plan to keep collecting info about investigational medical devices—those being tested for safety and effectiveness. This affects companies and researchers working on new medical devices, with no new costs or big changes, just a routine paperwork update. Comments are open until March 30, 2026, so now’s the time to speak up!
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Overall Paperwork Burden Increased
FDA estimates the total annual paperwork burden for investigational device exemptions increased by 9,919 hours and by 1,033 responses. The agency reports totals of 6,552 annual reporting responses (63,828 hours) and 6,059 recordkeeping records (11,994 hours), reflecting the higher workload for companies and researchers who submit IDE materials.
IDE Application Preparation Time
For investigational device exemption applications and investigational plans (21 CFR 812.20, 812.25, and 812.27), FDA estimates 288 responses annually with an average burden of 80 hours per response, totaling 23,040 hours each year. Other activity-level estimates include items such as 1,500 submissions accepting foreign clinical data averaging 10.25 hours each (15,375 hours).
Use of Leftover Specimens Without Consent
FDA’s guidance (GFI IVD Leftover Specimens April 2006) states the agency does not intend to object to use of leftover human specimens without informed consent if the specimens are not individually identifiable and the study meets the exemption criteria in 21 CFR 812.2(c)(3). This allows investigators to use remnants of specimens collected for routine clinical care in certain IDE studies while protecting subject privacy.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-03855 — Determination of Regulatory Review Period for Purposes of Patent Extension; LIMFLOW SYSTEM
The FDA has officially set the review period for the LIMFLOW SYSTEM, a medical device, so its patent can be extended. This affects the company behind LIMFLOW and anyone interested in patent timing or challenges. If you think the dates are wrong or the company wasn’t careful during review, you can speak up by April 27 or August 25, 2026.
Next: 2026-03858 — Combined Notice of Filings #1
The Federal Energy Regulatory Commission got several new filings from energy companies about accounting changes, new energy storage projects, and updates to electric rates. These changes could affect how some companies handle their money and operations, with public comments open until early to mid-March 2026. If you’re involved in energy or just curious, now’s the time to check in and have your say!